Abstract:История радиойодтерапии (РЙТ) началась в первой половине прошлого века. За многие годы была доказана эффективность, а во многих случаях и безальтернативность этого метода при лечении диффе-
“…Martinique hosted in 2018 and 2020 international consensus conferences, gathering European, American and Caribbean expertise in order to produce up-to-date guidelines, registered as “The Martinique Principles”, regarding interdisciplinary cooperation, therapy decision and use of radioiodine in thyroid cancer. The local impact of those new guidelines needs to be assessed in the future [ 11 ].…”
Background
Thyroid cancer (TC) overall survival at 5 years was estimated at 97% in mainland France over 2010–2015. Its prognosis is known to be affected by patient age, tumor histology, size, and extension. This study aims to describe overall survival of thyroid cancer patients diagnosed between 2008 and 2018 in Martinique.
Methods
We included in this retrospective analytical study all patients who were diagnosed with thyroid cancer. An overall survival analysis at 1, 3 and 5 years of thyroid cancer patients diagnosed in Martinique from 2008 to 2018 was conducted. Prognostic factors associated with survival have been identified. Stage at diagnosis and patterns of care among thyroid cancer patients were analyzed.
Results
A total of 323 thyroid cancer patients were registered between 2008 and 2018. Papillary carcinomas represented 83% of diagnoses. Local stage or locally advanced invasion was found in 264 (88%) patients. 221 Multidisciplinary Teams reports files were reviewed. The overall survival observed in this population is 97% [93–99] at 1 year, 93% [88–97] at 3 years and 91% [85–95] at 5 years. Anaplastic, poorly differentiated and medullar tumors had lower survival rates at 5 years (39% [13–65]) compared to papillary tumors (93% [89–96]). We found that metastatic stage at diagnosis (HR = 3.1[1.3–7.6]; p = 0.01) and tumor size > 3 cm (HR = 2.7 [1.1–6.3]) were independent prognostic factors for OS in our population.
Conclusions
The survival rates of thyroid cancer in Martinique are comparable to those observed in France.
“…Martinique hosted in 2018 and 2020 international consensus conferences, gathering European, American and Caribbean expertise in order to produce up-to-date guidelines, registered as “The Martinique Principles”, regarding interdisciplinary cooperation, therapy decision and use of radioiodine in thyroid cancer. The local impact of those new guidelines needs to be assessed in the future [ 11 ].…”
Background
Thyroid cancer (TC) overall survival at 5 years was estimated at 97% in mainland France over 2010–2015. Its prognosis is known to be affected by patient age, tumor histology, size, and extension. This study aims to describe overall survival of thyroid cancer patients diagnosed between 2008 and 2018 in Martinique.
Methods
We included in this retrospective analytical study all patients who were diagnosed with thyroid cancer. An overall survival analysis at 1, 3 and 5 years of thyroid cancer patients diagnosed in Martinique from 2008 to 2018 was conducted. Prognostic factors associated with survival have been identified. Stage at diagnosis and patterns of care among thyroid cancer patients were analyzed.
Results
A total of 323 thyroid cancer patients were registered between 2008 and 2018. Papillary carcinomas represented 83% of diagnoses. Local stage or locally advanced invasion was found in 264 (88%) patients. 221 Multidisciplinary Teams reports files were reviewed. The overall survival observed in this population is 97% [93–99] at 1 year, 93% [88–97] at 3 years and 91% [85–95] at 5 years. Anaplastic, poorly differentiated and medullar tumors had lower survival rates at 5 years (39% [13–65]) compared to papillary tumors (93% [89–96]). We found that metastatic stage at diagnosis (HR = 3.1[1.3–7.6]; p = 0.01) and tumor size > 3 cm (HR = 2.7 [1.1–6.3]) were independent prognostic factors for OS in our population.
Conclusions
The survival rates of thyroid cancer in Martinique are comparable to those observed in France.
Children are not “miniature” adults! Most experts around the world recognize the differences between adult and pediatric thyroid cancer and emphasize the need for specific guidelines for the pediatric population. The American Thyroid Association (ATA) first developed separate Guidelines for the Treatment of Pediatric Thyroid Nodules and Carcinoma (hereafter, ATA Guidelines) in 2015 [1], which has not been revised to date. In September 2022, the European Thyroid Association (ETA) published its Guideline on the Management of Pediatric Thyroid Nodules and Differentiated Thyroid Carcinoma (hereafter, ETA Guidelines) [2]. The aim of our article, in anticipation of the revision of Russian clinical guidelines for the treatment of pediatric thyroid cancer, is to inform specialists in the field of radioiodine therapy (RIT) with the key recommendations of the ETA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.